ReviewCurrent addiction reports2025
A Narrative Review of Research on Cannabis Advertising in the United States.
Review in Current addiction reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Characterizing public comments via Regulations.gov in response to proposed cannabis rescheduling in the United States.Addiction (Abingdon, England) · 2026Article
- Marketing features of derived intoxicating cannabinoid product brands on Instagram: A content analysis.Addiction (Abingdon, England) · 2026Article
- Impact of Simple Versus Complex Cannabis Advertising Messages and Warnings on US Young Adults' Product Perceptions.Substance use & addiction journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Purpose of Review: In the U.S., cannabis products containing at least 0.3% tetrahydrocannabinol (THC), are legal for adult use in 22 states (including the District of Columbia) and in 16 additional states for medicinal use. There is a growing body of literature to understand how these products are marketed. The objective of this narrative review is to summarize recent research examining cannabis advertising. We characterized the research reviewed across three primary domains: (1) content of cannabis advertising; (2) prevalence of cannabis advertising exposure; and (3) effects of cannabis advertising on user perceptions. Recent Findings: Research indicates that cannabis is marketed in a variety of ways, including via tactics (e.g., price promotions) found to be effective in increasing use of other commercial products (e.g., tobacco). Moreover, cannabis marketing tactics may be appealing to youth or mislead consumers via unsubstantiated health claims. Exposure to cannabis advertising is common among both youth and adults, occurring through a variety of pathways including storefront signage, social media and billboards. Finally, several studies have found associations between exposure to cannabis marketing and cannabis use; however, studies designed to estimate causal effects of exposure were limited, warranting additional research in this area. Summary: Understanding the prevalence and effects of exposure to cannabis advertising, along with the content of this advertising, can inform the operationalization and implementation of regulations and interventions designed to mitigate harms associated with advertising exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.